Waters (NYSE:WAT – Free Report) had its price target raised by Stifel Nicolaus from $290.00 to $330.00 in a research report sent to investors on Wednesday, Benzinga reports. Stifel Nicolaus currently has a hold rating on the medical instruments supplier’s stock.
Several other equities analysts have also recently weighed in on the company. Wolfe Research started coverage on Waters in a research note on Wednesday, December 13th. They set a peer perform rating on the stock. JPMorgan Chase & Co. dropped their price objective on Waters from $260.00 to $250.00 and set a neutral rating on the stock in a research note on Wednesday, November 8th. Barclays raised their price objective on Waters from $230.00 to $275.00 and gave the company an underweight rating in a research note on Thursday, January 25th. Citigroup raised their price objective on Waters from $265.00 to $300.00 and gave the company a neutral rating in a research note on Monday, December 11th. Finally, TheStreet upgraded Waters from a c+ rating to a b- rating in a research note on Wednesday, December 13th. One equities research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the company. According to MarketBeat, Waters currently has a consensus rating of Hold and a consensus target price of $290.38.
Waters Price Performance
Waters (NYSE:WAT – Get Free Report) last issued its earnings results on Tuesday, February 6th. The medical instruments supplier reported $3.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.56 by $0.06. Waters had a return on equity of 81.30% and a net margin of 21.72%. The company had revenue of $819.50 million for the quarter, compared to analysts’ expectations of $815.50 million. During the same period last year, the business earned $3.84 EPS. Waters’s quarterly revenue was down 4.5% compared to the same quarter last year. Sell-side analysts anticipate that Waters will post 11.9 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Waters
A number of hedge funds and other institutional investors have recently made changes to their positions in WAT. First Capital Advisors Group LLC. bought a new stake in Waters in the 2nd quarter valued at about $26,000. Institutional & Family Asset Management LLC bought a new stake in Waters in the 2nd quarter valued at about $27,000. West Tower Group LLC bought a new stake in Waters in the 2nd quarter valued at about $28,000. Harbour Investments Inc. raised its stake in Waters by 11,000.0% in the 2nd quarter. Harbour Investments Inc. now owns 111 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 110 shares during the period. Finally, Private Trust Co. NA raised its stake in Waters by 55.3% in the 3rd quarter. Private Trust Co. NA now owns 118 shares of the medical instruments supplier’s stock valued at $32,000 after acquiring an additional 42 shares during the period. 94.01% of the stock is owned by hedge funds and other institutional investors.
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
- Five stocks we like better than Waters
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Cloudflare results spark analysts reset: 25% upside ahead
- Following Congress Stock Trades
- Beyond Nvidia: The hidden stars with 200% earnings growth
- Find and Profitably Trade Stocks at 52-Week Lows
- 3 large caps with RSIs that scream ‘oversold’
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.